Learn More About Trodelvy Patient Support Services

2021 Year in Review - Triple-Negative Breast Cancer —January 20, 2022

Categories:

Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) copayment assistance, reimbursement support, and patient assistance programs are available for eligible patients.1 Prior authorizations and appeals must be submitted by the physician’s office.2 Patients with any type of government insurance are not eligible for the Trodelvy Savings Program.2 To be eligible for this program, patients must meet certain criteria. The patient pays no out-of-pocket costs for Trodelvy once enrolled, with a maximum benefit of $25,000 per year.2

The Gilead Patient Assistance Program provides free access to Trodelvy for patients who are uninsured or underinsured.2 Patients must meet specific eligibility requirements to qualify for assistance.2

Patients with Medicare or other government insurance who require copay or coinsurance assistance for Trodelvy may be eligible for assistance from an independent copay assistance foundation.2 Patients can work with case managers to determine their high-level eligibility for Trodelvy coverage through an independent copay assistance foundation.2 Case managers and nurse navigators can provide information on any available foundations if copay assistance is needed. A foundation will determine the patient’s eligibility for copay or coinsurance assistance based on their individual criteria and will contact the patient directly on the application process, fully independent of Gilead and its agents. Gilead and its representatives make no assurances about compensation for any service or material.2

The Trodelvy Savings Program is for commercially or privately insured patients, offering up to $25,000 in savings on out-of-pocket payments for Trodelvy 180-mg single-dose vials. Only the cost of Trodelvy is covered by the program; the patient is responsible for the cost of treatments and office visits.2

Any claims funded, paid, or reimbursed in whole or in part by Medicaid, Medicare, or other federal or state healthcare programs are not supported by this program.2

Trodelvy Access Support case managers can provide information about independent third-party groups that may be able to help with the cost of treatment to patients who are unable to afford their medication (including those with Medicare, Medicaid, or other government-sponsored insurance). Trodelvy coverage, coding, and billing requirements vary by plan and patient.2

Further information can be found at https://trodelvyhcp.com/hcp/mTNBC/access-support or www.needymeds.org/brand-drug/name/Trodelvy.

References

  1. Needymeds.com. Trodelvy. Updated September 2021. www.needymeds.org/brand-drug/name/Trodelvy. Accessed November 15, 2021.
  2. Trodelvyhcp.com. Trodelvy access support. Updated September 2021. https://trodelvyhcp.com/hcp/mTNBC/access-support. Accessed November 15, 2021.
Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
|
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
Video Library
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Improving Adherence to Oral Oncolytics in Breast Cancer: The Pivotal Role of Nurse Navigators
September 2022 Vol 13, No 9
Oral oncolytic drugs have a multitude of benefits for patients, including ease of use, improved quality of life, fewer clinic visits, and no need for IV therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country